The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD
Background The Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies Chronic Obstructive Pulmonary Disease (COPD) into groups based on symptoms, exacerbations and forced expiratory volume in one second (FEV 1 ). This allows patients to change to less severe COPD sta...
Gespeichert in:
| Veröffentlicht in: | Respiratory research Jg. 19; H. 1; S. 249 - 10 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
BioMed Central
12.12.2018
BioMed Central Ltd Nature Publishing Group BMC |
| Schlagworte: | |
| ISSN: | 1465-993X, 1465-9921, 1465-993X |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies Chronic Obstructive Pulmonary Disease (COPD) into groups based on symptoms, exacerbations and forced expiratory volume in one second (FEV
1
). This allows patients to change to less severe COPD stages, a novel aspect of assessment not previously evaluated. We aimed to investigate the association between temporal changes in GOLD severity stage and outcomes in COPD patients.
Methods
This was a record-linkage study using patients registered with a Scottish regional COPD network 2000–2015. Annual spirometry & symptoms were recorded and linked to healthcare records to identify exacerbations, hospitalisations and mortality. Spirometry, modified Medical Research Council (mMRC) dyspnoea scale and acute exacerbations over the previous year were used to assign GOLD severity at each visit. A time-dependent Cox model was used to model time to death. Secondary outcomes were respiratory specific mortality and hospitalisations. Effect sizes are expressed as Hazard Ratios HR (95%CI).
Results
Four thousand, eight hundred and eighty-five patients (mean age 67.3 years; 51.3% female) with 21,348 visits were included. During a median 6.6 years follow-up there were 1530 deaths. For the secondary outcomes there were 712 respiratory deaths and 1629 first hospitalisations. Across 16,463 visit-pairs, improvement in COPD severity was seen in 2308 (14%), no change in 11,010 (66.9%) and worsening in 3145 (19.1). Compared to patients staying in GOLD stage A, those worsening had a stepwise increased mortality and hospitalisations.
Conclusions
Improving COPD severity classification was associated with reduced mortality and worsening COPD severity was associated with increased mortality and hospitalisations. Change in GOLD group has potential as monitoring tool and outcome measure in clinical trials. |
|---|---|
| AbstractList | Background The Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies Chronic Obstructive Pulmonary Disease (COPD) into groups based on symptoms, exacerbations and forced expiratory volume in one second (FEV1). This allows patients to change to less severe COPD stages, a novel aspect of assessment not previously evaluated. We aimed to investigate the association between temporal changes in GOLD severity stage and outcomes in COPD patients. Methods This was a record-linkage study using patients registered with a Scottish regional COPD network 2000–2015. Annual spirometry & symptoms were recorded and linked to healthcare records to identify exacerbations, hospitalisations and mortality. Spirometry, modified Medical Research Council (mMRC) dyspnoea scale and acute exacerbations over the previous year were used to assign GOLD severity at each visit. A time-dependent Cox model was used to model time to death. Secondary outcomes were respiratory specific mortality and hospitalisations. Effect sizes are expressed as Hazard Ratios HR (95%CI). Results Four thousand, eight hundred and eighty-five patients (mean age 67.3 years; 51.3% female) with 21,348 visits were included. During a median 6.6 years follow-up there were 1530 deaths. For the secondary outcomes there were 712 respiratory deaths and 1629 first hospitalisations. Across 16,463 visit-pairs, improvement in COPD severity was seen in 2308 (14%), no change in 11,010 (66.9%) and worsening in 3145 (19.1). Compared to patients staying in GOLD stage A, those worsening had a stepwise increased mortality and hospitalisations. Conclusions Improving COPD severity classification was associated with reduced mortality and worsening COPD severity was associated with increased mortality and hospitalisations. Change in GOLD group has potential as monitoring tool and outcome measure in clinical trials. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies Chronic Obstructive Pulmonary Disease (COPD) into groups based on symptoms, exacerbations and forced expiratory volume in one second (FEV1). This allows patients to change to less severe COPD stages, a novel aspect of assessment not previously evaluated. We aimed to investigate the association between temporal changes in GOLD severity stage and outcomes in COPD patients.BACKGROUNDThe Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies Chronic Obstructive Pulmonary Disease (COPD) into groups based on symptoms, exacerbations and forced expiratory volume in one second (FEV1). This allows patients to change to less severe COPD stages, a novel aspect of assessment not previously evaluated. We aimed to investigate the association between temporal changes in GOLD severity stage and outcomes in COPD patients.This was a record-linkage study using patients registered with a Scottish regional COPD network 2000-2015. Annual spirometry & symptoms were recorded and linked to healthcare records to identify exacerbations, hospitalisations and mortality. Spirometry, modified Medical Research Council (mMRC) dyspnoea scale and acute exacerbations over the previous year were used to assign GOLD severity at each visit. A time-dependent Cox model was used to model time to death. Secondary outcomes were respiratory specific mortality and hospitalisations. Effect sizes are expressed as Hazard Ratios HR (95%CI).METHODSThis was a record-linkage study using patients registered with a Scottish regional COPD network 2000-2015. Annual spirometry & symptoms were recorded and linked to healthcare records to identify exacerbations, hospitalisations and mortality. Spirometry, modified Medical Research Council (mMRC) dyspnoea scale and acute exacerbations over the previous year were used to assign GOLD severity at each visit. A time-dependent Cox model was used to model time to death. Secondary outcomes were respiratory specific mortality and hospitalisations. Effect sizes are expressed as Hazard Ratios HR (95%CI).Four thousand, eight hundred and eighty-five patients (mean age 67.3 years; 51.3% female) with 21,348 visits were included. During a median 6.6 years follow-up there were 1530 deaths. For the secondary outcomes there were 712 respiratory deaths and 1629 first hospitalisations. Across 16,463 visit-pairs, improvement in COPD severity was seen in 2308 (14%), no change in 11,010 (66.9%) and worsening in 3145 (19.1). Compared to patients staying in GOLD stage A, those worsening had a stepwise increased mortality and hospitalisations.RESULTSFour thousand, eight hundred and eighty-five patients (mean age 67.3 years; 51.3% female) with 21,348 visits were included. During a median 6.6 years follow-up there were 1530 deaths. For the secondary outcomes there were 712 respiratory deaths and 1629 first hospitalisations. Across 16,463 visit-pairs, improvement in COPD severity was seen in 2308 (14%), no change in 11,010 (66.9%) and worsening in 3145 (19.1). Compared to patients staying in GOLD stage A, those worsening had a stepwise increased mortality and hospitalisations.Improving COPD severity classification was associated with reduced mortality and worsening COPD severity was associated with increased mortality and hospitalisations. Change in GOLD group has potential as monitoring tool and outcome measure in clinical trials.CONCLUSIONSImproving COPD severity classification was associated with reduced mortality and worsening COPD severity was associated with increased mortality and hospitalisations. Change in GOLD group has potential as monitoring tool and outcome measure in clinical trials. Background The Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies Chronic Obstructive Pulmonary Disease (COPD) into groups based on symptoms, exacerbations and forced expiratory volume in one second (FEV 1 ). This allows patients to change to less severe COPD stages, a novel aspect of assessment not previously evaluated. We aimed to investigate the association between temporal changes in GOLD severity stage and outcomes in COPD patients. Methods This was a record-linkage study using patients registered with a Scottish regional COPD network 2000–2015. Annual spirometry & symptoms were recorded and linked to healthcare records to identify exacerbations, hospitalisations and mortality. Spirometry, modified Medical Research Council (mMRC) dyspnoea scale and acute exacerbations over the previous year were used to assign GOLD severity at each visit. A time-dependent Cox model was used to model time to death. Secondary outcomes were respiratory specific mortality and hospitalisations. Effect sizes are expressed as Hazard Ratios HR (95%CI). Results Four thousand, eight hundred and eighty-five patients (mean age 67.3 years; 51.3% female) with 21,348 visits were included. During a median 6.6 years follow-up there were 1530 deaths. For the secondary outcomes there were 712 respiratory deaths and 1629 first hospitalisations. Across 16,463 visit-pairs, improvement in COPD severity was seen in 2308 (14%), no change in 11,010 (66.9%) and worsening in 3145 (19.1). Compared to patients staying in GOLD stage A, those worsening had a stepwise increased mortality and hospitalisations. Conclusions Improving COPD severity classification was associated with reduced mortality and worsening COPD severity was associated with increased mortality and hospitalisations. Change in GOLD group has potential as monitoring tool and outcome measure in clinical trials. Background The Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies Chronic Obstructive Pulmonary Disease (COPD) into groups based on symptoms, exacerbations and forced expiratory volume in one second (FEV.sub.1). This allows patients to change to less severe COPD stages, a novel aspect of assessment not previously evaluated. We aimed to investigate the association between temporal changes in GOLD severity stage and outcomes in COPD patients. Methods This was a record-linkage study using patients registered with a Scottish regional COPD network 2000-2015. Annual spirometry & symptoms were recorded and linked to healthcare records to identify exacerbations, hospitalisations and mortality. Spirometry, modified Medical Research Council (mMRC) dyspnoea scale and acute exacerbations over the previous year were used to assign GOLD severity at each visit. A time-dependent Cox model was used to model time to death. Secondary outcomes were respiratory specific mortality and hospitalisations. Effect sizes are expressed as Hazard Ratios HR (95%CI). Results Four thousand, eight hundred and eighty-five patients (mean age 67.3 years; 51.3% female) with 21,348 visits were included. During a median 6.6 years follow-up there were 1530 deaths. For the secondary outcomes there were 712 respiratory deaths and 1629 first hospitalisations. Across 16,463 visit-pairs, improvement in COPD severity was seen in 2308 (14%), no change in 11,010 (66.9%) and worsening in 3145 (19.1). Compared to patients staying in GOLD stage A, those worsening had a stepwise increased mortality and hospitalisations. Conclusions Improving COPD severity classification was associated with reduced mortality and worsening COPD severity was associated with increased mortality and hospitalisations. Change in GOLD group has potential as monitoring tool and outcome measure in clinical trials. Keywords: Chronic obstructive pulmonary disease, Global initiative for chronic obstructive lung disease (GOLD), Mortality, Morbidity The Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies Chronic Obstructive Pulmonary Disease (COPD) into groups based on symptoms, exacerbations and forced expiratory volume in one second (FEV.sub.1). This allows patients to change to less severe COPD stages, a novel aspect of assessment not previously evaluated. We aimed to investigate the association between temporal changes in GOLD severity stage and outcomes in COPD patients. This was a record-linkage study using patients registered with a Scottish regional COPD network 2000-2015. Annual spirometry & symptoms were recorded and linked to healthcare records to identify exacerbations, hospitalisations and mortality. Spirometry, modified Medical Research Council (mMRC) dyspnoea scale and acute exacerbations over the previous year were used to assign GOLD severity at each visit. A time-dependent Cox model was used to model time to death. Secondary outcomes were respiratory specific mortality and hospitalisations. Effect sizes are expressed as Hazard Ratios HR (95%CI). Four thousand, eight hundred and eighty-five patients (mean age 67.3 years; 51.3% female) with 21,348 visits were included. During a median 6.6 years follow-up there were 1530 deaths. For the secondary outcomes there were 712 respiratory deaths and 1629 first hospitalisations. Across 16,463 visit-pairs, improvement in COPD severity was seen in 2308 (14%), no change in 11,010 (66.9%) and worsening in 3145 (19.1). Compared to patients staying in GOLD stage A, those worsening had a stepwise increased mortality and hospitalisations. Improving COPD severity classification was associated with reduced mortality and worsening COPD severity was associated with increased mortality and hospitalisations. Change in GOLD group has potential as monitoring tool and outcome measure in clinical trials. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies Chronic Obstructive Pulmonary Disease (COPD) into groups based on symptoms, exacerbations and forced expiratory volume in one second (FEV ). This allows patients to change to less severe COPD stages, a novel aspect of assessment not previously evaluated. We aimed to investigate the association between temporal changes in GOLD severity stage and outcomes in COPD patients. This was a record-linkage study using patients registered with a Scottish regional COPD network 2000-2015. Annual spirometry & symptoms were recorded and linked to healthcare records to identify exacerbations, hospitalisations and mortality. Spirometry, modified Medical Research Council (mMRC) dyspnoea scale and acute exacerbations over the previous year were used to assign GOLD severity at each visit. A time-dependent Cox model was used to model time to death. Secondary outcomes were respiratory specific mortality and hospitalisations. Effect sizes are expressed as Hazard Ratios HR (95%CI). Four thousand, eight hundred and eighty-five patients (mean age 67.3 years; 51.3% female) with 21,348 visits were included. During a median 6.6 years follow-up there were 1530 deaths. For the secondary outcomes there were 712 respiratory deaths and 1629 first hospitalisations. Across 16,463 visit-pairs, improvement in COPD severity was seen in 2308 (14%), no change in 11,010 (66.9%) and worsening in 3145 (19.1). Compared to patients staying in GOLD stage A, those worsening had a stepwise increased mortality and hospitalisations. Improving COPD severity classification was associated with reduced mortality and worsening COPD severity was associated with increased mortality and hospitalisations. Change in GOLD group has potential as monitoring tool and outcome measure in clinical trials. Abstract Background The Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies Chronic Obstructive Pulmonary Disease (COPD) into groups based on symptoms, exacerbations and forced expiratory volume in one second (FEV1). This allows patients to change to less severe COPD stages, a novel aspect of assessment not previously evaluated. We aimed to investigate the association between temporal changes in GOLD severity stage and outcomes in COPD patients. Methods This was a record-linkage study using patients registered with a Scottish regional COPD network 2000–2015. Annual spirometry & symptoms were recorded and linked to healthcare records to identify exacerbations, hospitalisations and mortality. Spirometry, modified Medical Research Council (mMRC) dyspnoea scale and acute exacerbations over the previous year were used to assign GOLD severity at each visit. A time-dependent Cox model was used to model time to death. Secondary outcomes were respiratory specific mortality and hospitalisations. Effect sizes are expressed as Hazard Ratios HR (95%CI). Results Four thousand, eight hundred and eighty-five patients (mean age 67.3 years; 51.3% female) with 21,348 visits were included. During a median 6.6 years follow-up there were 1530 deaths. For the secondary outcomes there were 712 respiratory deaths and 1629 first hospitalisations. Across 16,463 visit-pairs, improvement in COPD severity was seen in 2308 (14%), no change in 11,010 (66.9%) and worsening in 3145 (19.1). Compared to patients staying in GOLD stage A, those worsening had a stepwise increased mortality and hospitalisations. Conclusions Improving COPD severity classification was associated with reduced mortality and worsening COPD severity was associated with increased mortality and hospitalisations. Change in GOLD group has potential as monitoring tool and outcome measure in clinical trials. |
| ArticleNumber | 249 |
| Audience | Academic |
| Author | Chalmers, James D. Schembri, Stuart MacDonald, Thomas M. Flynn, Robert W. V. |
| Author_xml | – sequence: 1 givenname: Robert W. V. surname: Flynn fullname: Flynn, Robert W. V. email: rob@memo.dundee.ac.uk organization: Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School – sequence: 2 givenname: Thomas M. surname: MacDonald fullname: MacDonald, Thomas M. organization: Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School – sequence: 3 givenname: James D. surname: Chalmers fullname: Chalmers, James D. organization: Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School – sequence: 4 givenname: Stuart surname: Schembri fullname: Schembri, Stuart organization: Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30541559$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1rFDEYxgep2A_9A7xIwEsvU5PJ1-QilK3WwsJ6qKCnkMkks1lmkppkC_3vzbi17RaVHPL1e57kfXmOqwMfvKmqtwieIdSyDwk1AqMaoraGgsEav6iOEGG0FgJ_P3iyPqyOU9pAiHjL6avqEENKEKXiqPpxvTbAWGt0BsECvVZ-MAnkAC5XywuQzK2JLt-BlNVgQPBgDH4A2cQJTCF2rp8vle_nXVbjvHMeLFZfL15XL60ak3lzP59U3z5_ul58qZery6vF-bLWDOJcC9gZ0XKrtbDCdE2DBbKWcV6-pDusoMAdbJTumdEttrhHtIG6pVqhntCW4JPqaufbB7WRN9FNKt7JoJz8fRDiIFXMTo9GIkusUJQxhhmxLVet7rniSCGiMBNd8fq487rZdpPptfE5qnHPdP_Gu7Ucwq1kjUCCsGJwem8Qw8-tSVlOLmkzjsqbsE2ymbtOGo5QQd8_QzdhG31p1Uy1iBKI2SM1qFKA8zaUd_VsKs8pExBDRHihzv5CldGbyekSGuvK-Z7g3dNCHyr8E4wCoB2gY0gpGvuAICjn8Mld-GQJn5zDJ3HR8Gca7bLKLsy9cuN_lc1OmcorJYDxsRf_Fv0CFfLrVw |
| CitedBy_id | crossref_primary_10_1093_ehjcvp_pvz052 crossref_primary_10_3390_cells13161351 crossref_primary_10_1016_j_jaci_2020_02_040 crossref_primary_10_3390_medicina58020163 crossref_primary_10_1183_23120541_00253_2020 crossref_primary_10_1186_s12906_020_03104_1 crossref_primary_10_3390_jcm12165322 crossref_primary_10_1177_17534666241232768 crossref_primary_10_7189_jogh_15_04055 crossref_primary_10_2147_COPD_S492178 |
| Cites_doi | 10.1016/0021-9681(87)90171-8 10.1186/s12931-014-0141-y 10.2147/COPD.S136023 10.1136/thorax.56.11.880 10.1056/NEJMoa1105482 10.1056/NEJMe0807387 10.1183/13993003.00214-2017 10.1183/09031936.00195212 10.1186/1465-9921-15-3 10.1164/rccm.201207-1299OC 10.1378/chest.12-1053 10.1136/bmj.1.6077.1645 10.1164/rccm.201212-2276OC 10.1016/j.rmed.2009.04.021 10.1186/1465-9921-12-40 10.1016/j.rmed.2006.04.001 10.1136/thoraxjnl-2014-205770 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2018 COPYRIGHT 2018 BioMed Central Ltd. Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2018 – notice: COPYRIGHT 2018 BioMed Central Ltd. – notice: Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7U7 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12931-018-0960-3 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Databases ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts Toxicology Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Open Access资源_DOAJ url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest - Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1465-993X |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_1f4f9a5666364f87a8cd7a71a14a369b PMC6291946 A569030147 30541559 10_1186_s12931_018_0960_3 |
| Genre | Journal Article Observational Study |
| GeographicLocations | Scotland |
| GeographicLocations_xml | – name: Scotland |
| GrantInformation_xml | – fundername: GlaxoSmithKline funderid: http://dx.doi.org/10.13039/100004330 – fundername: ; |
| GroupedDBID | --- 0R~ 29P 2WC 4.4 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR IPNFZ ITC KQ8 M1P M48 O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RIG RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7QL 7U7 7U9 7XB 8FK AZQEC C1K DWQXO H94 K9. M7N PKEHL PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c603t-90be987fcc9f9eb22391ff677feccb3a093b02acd6ec83f3d1520c85ca1d45843 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 12 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000453061900003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1465-993X 1465-9921 |
| IngestDate | Fri Oct 03 12:45:29 EDT 2025 Tue Nov 04 02:00:34 EST 2025 Sun Nov 09 11:50:53 EST 2025 Mon Oct 06 18:11:16 EDT 2025 Tue Nov 11 10:31:54 EST 2025 Tue Nov 04 17:59:21 EST 2025 Mon Jul 21 06:05:52 EDT 2025 Sat Nov 29 03:57:48 EST 2025 Tue Nov 18 21:52:33 EST 2025 Sat Sep 06 07:28:54 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Chronic obstructive pulmonary disease Global initiative for chronic obstructive lung disease (GOLD) Mortality Morbidity |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c603t-90be987fcc9f9eb22391ff677feccb3a093b02acd6ec83f3d1520c85ca1d45843 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://doaj.org/article/1f4f9a5666364f87a8cd7a71a14a369b |
| PMID | 30541559 |
| PQID | 2158154036 |
| PQPubID | 42864 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1f4f9a5666364f87a8cd7a71a14a369b pubmedcentral_primary_oai_pubmedcentral_nih_gov_6291946 proquest_miscellaneous_2155942711 proquest_journals_2158154036 gale_infotracmisc_A569030147 gale_infotracacademiconefile_A569030147 pubmed_primary_30541559 crossref_primary_10_1186_s12931_018_0960_3 crossref_citationtrail_10_1186_s12931_018_0960_3 springer_journals_10_1186_s12931_018_0960_3 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-12-12 |
| PublicationDateYYYYMMDD | 2018-12-12 |
| PublicationDate_xml | – month: 12 year: 2018 text: 2018-12-12 day: 12 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Respiratory research |
| PublicationTitleAbbrev | Respir Res |
| PublicationTitleAlternate | Respir Res |
| PublicationYear | 2018 |
| Publisher | BioMed Central BioMed Central Ltd Nature Publishing Group BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Nature Publishing Group – name: BMC |
| References | C Fletcher (960_CR3) 1977; 1 P Lange (960_CR6) 2012; 186 J Vestbo (960_CR4) 2011; 365 World Health Organization (960_CR15) 1992 L Wei (960_CR12) 2005 ME Charlson (960_CR18) 1987; 40 Global Initiative for Chronic Obstructive Lung Disease (960_CR1) 2007 C Casanova (960_CR8) 2014; 15 World Health Organization (960_CR14) 1977 960_CR23 JJ Reilly (960_CR11) 2008; 359 960_CR2 A Agusti (960_CR10) 2013; 42 RW Flynn (960_CR17) 2014; 15 T Oga (960_CR20) 2007; 101 PW Jones (960_CR21) 2001; 56 A Johannessen (960_CR7) 2013; 188 M Westwood (960_CR19) 2011; 12 S Schembri (960_CR13) 2009; 103 JP Torres de (960_CR5) 2014; 69 Office of Population Censuses and Surveys (960_CR16) 1990 AM Menezes (960_CR9) 2017; 12 JB Soriano (960_CR22) 2013; 143 |
| References_xml | – volume: 40 start-page: 373 year: 1987 ident: 960_CR18 publication-title: J Chronic Dis doi: 10.1016/0021-9681(87)90171-8 – volume-title: Global strategy for the diagnosis, management, and prevention of COPD year: 2007 ident: 960_CR1 – volume-title: Tabular List of the Classification of Surgical Operations and Procedures Fourth Revision year: 1990 ident: 960_CR16 – volume: 15 start-page: 141 year: 2014 ident: 960_CR17 publication-title: Respir Res doi: 10.1186/s12931-014-0141-y – volume: 12 start-page: 1491 year: 2017 ident: 960_CR9 publication-title: Int J Chron Obstruct Pulmon Dis doi: 10.2147/COPD.S136023 – volume: 56 start-page: 880 year: 2001 ident: 960_CR21 publication-title: Thorax doi: 10.1136/thorax.56.11.880 – volume: 365 start-page: 1184 year: 2011 ident: 960_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa1105482 – volume: 359 start-page: 1616 year: 2008 ident: 960_CR11 publication-title: N Engl J Med doi: 10.1056/NEJMe0807387 – ident: 960_CR23 doi: 10.1183/13993003.00214-2017 – volume: 42 start-page: 636 year: 2013 ident: 960_CR10 publication-title: Eur Respir J doi: 10.1183/09031936.00195212 – start-page: xvii, 889 volume-title: Pharmacoepidemiology year: 2005 ident: 960_CR12 – volume: 15 start-page: 3 year: 2014 ident: 960_CR8 publication-title: Respir Res doi: 10.1186/1465-9921-15-3 – volume-title: International classification of Diseases & Related Health Problems 10th rev year: 1992 ident: 960_CR15 – volume-title: Manual of the international classification of diseases, injuries and causes of death 9th rev year: 1977 ident: 960_CR14 – ident: 960_CR2 – volume: 186 start-page: 975 year: 2012 ident: 960_CR6 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201207-1299OC – volume: 143 start-page: 694 year: 2013 ident: 960_CR22 publication-title: Chest doi: 10.1378/chest.12-1053 – volume: 1 start-page: 1645 year: 1977 ident: 960_CR3 publication-title: Br Med J doi: 10.1136/bmj.1.6077.1645 – volume: 188 start-page: 51 year: 2013 ident: 960_CR7 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201212-2276OC – volume: 103 start-page: 1461 year: 2009 ident: 960_CR13 publication-title: Respir Med doi: 10.1016/j.rmed.2009.04.021 – volume: 12 start-page: 40 year: 2011 ident: 960_CR19 publication-title: Respir Res doi: 10.1186/1465-9921-12-40 – volume: 101 start-page: 146 year: 2007 ident: 960_CR20 publication-title: Respir Med doi: 10.1016/j.rmed.2006.04.001 – volume: 69 start-page: 799 year: 2014 ident: 960_CR5 publication-title: Thorax doi: 10.1136/thoraxjnl-2014-205770 |
| SSID | ssj0017875 |
| Score | 2.3017948 |
| Snippet | Background
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies Chronic Obstructive Pulmonary Disease (COPD) into groups... The Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies Chronic Obstructive Pulmonary Disease (COPD) into groups based on... Background The Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies Chronic Obstructive Pulmonary Disease (COPD) into groups... Abstract Background The Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies Chronic Obstructive Pulmonary Disease (COPD)... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 249 |
| SubjectTerms | Aged Analysis Chronic obstructive lung disease Chronic obstructive pulmonary disease Classification Clinical trials Cohort Studies Dyspnea Fatalities Female Follow-Up Studies Forced Expiratory Volume - physiology Global Health - trends Global initiative for chronic obstructive lung disease (GOLD) Gold Health aspects Humans Longitudinal Studies Lung diseases Male Medical research Medicine Medicine & Public Health Middle Aged Morbidity Morbidity - trends Mortality Mortality - trends Obstructive lung disease Patients Pneumology/Respiratory System Pulmonary Disease, Chronic Obstructive - diagnosis Pulmonary Disease, Chronic Obstructive - mortality Pulmonary Disease, Chronic Obstructive - physiopathology Respiration Respiratory Function Tests - mortality Respiratory Function Tests - trends Scotland - epidemiology Severity of Illness Index Spirometry - mortality Spirometry - trends Studies Time dependence |
| SummonAdditionalLinks | – databaseName: Publicly Available Content Database dbid: PIMPY link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELegQ4gXvmGBgYyEhASKGseOHT-hsTFA2kcfAG1Plu3EpdKWjLbj7-cucTsyxJ54bO2ovvrn393lzneEvHaqqLizKhVO5KnwQqZWuyx14I045oWXXYLs9311eFgeH-tJvB69iGmVK07siLqv9ox520DC46r1-MZ8DIqqBOUP9Pv-_GeKPaQw1hobatwkG1h4qxyRjcmXg8nJOqoA4Cz620ZFqnXOYpSTlXK8QL2HjjUmA0igpoGe6sr5_03af2itqxmVV8Kqnbbau_d_5bxP7karlW73MHtAbtTNQ3L7IMblH5ETQBvtU0NoG2h_m3hBly39dLS_S0H71tgkj4IpOq1p29DTtplS1Ar0rJ27WYWDtqnw07LzDOisoTtHk93H5Nvex687n9PYtCH1MuPLVGeu1qUK3uugwW3PuWYhSKVgCd5xm2nustz6Sta-5IFXYEBkviy8ZRXGbPkTMmrapt4k1PGQBeGroJkVoWZOAhuWDExI6TjgKCHZaouMjxXNsbHGqek8m1KaflcN7KrBXTU8IW_Xj5z35Tyum_wB9309EStxd1-086mJB9uwIIK2YBRLLkUolS19paxilgnLpXYJeYOoMcgXsDhv47UHEBErb5ntQurOr1UJ2RrMhHPuh8MrwJjIMwtziY-EvFoP45OYO9fU7UU3p9AiV4wl5GkP07VIwPZoUeqEqAGABzIPR5rZj64Kucw10wJ-990K6pfL-udf-ux6IZ6TOzkeQYYNd7bIaDm_qF-QW_7XcraYv4zH-Tfhy1Ve priority: 102 providerName: ProQuest – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELagIMQL9xEoyEhISKCocez18VhaCg-lrTiq8mTZTrysVBK0m_L7mXGShZRDgsfEtmI738x8oxmPCXnq1azi3qlceFHmIgiZO-OL3IM34lkQQaYE2eN9dXCgT07M0XCOezVmu48hyaSpk1hrubVCy4SuL4brJSiPi-QSWDuN0vju_fE6dAAInA3hy98OmxigVKf_V238kzk6nyp5Ll6azNDe9f9awA1ybWCddLuHyU1yoW5ukStvh7j6bfIJ0EL71A7aRtqfBl7RrqWvD_d3KVjPGi-5o0Al5zVtG3raNnOKWp1-aZd-UWGjayp86hKzp4uG7hwe7d4hH_defdh5kw-XLuRBFrzLTeFro1UMwUQDbnfJDYtRKgVTCJ67wnBflC5Usg6aR14BASiCngXHKoy58rtko2mb-j6hnsciilBFw5yINfMStJlmQAGl54CDjBTjn7BhqEiOF2Oc2uSZaGn7LbOwZRa3zPKMPF8P-dqX4_hb55f4e9cdsZJ2etEu53YQTMuiiMYBqZVciqiV06FSTjHHhOPS-Iw8Q3BYlHeYXHDDsQVYIlbOstszaZJfqjKyOekJchqmzSO87KAnVhYIlwYSCzQiI0_WzTgSc9-auj1LfWZGlIqxjNzr0bheEmhrZIQmI2qC08mapy3N4nOqIi5Lw4yA774Y0fpjWn_c0gf_1PshuVoi3Bnen7NJNrrlWf2IXA7fusVq-TiJ7XfpGjwc priority: 102 providerName: Springer Nature |
| Title | The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD |
| URI | https://link.springer.com/article/10.1186/s12931-018-0960-3 https://www.ncbi.nlm.nih.gov/pubmed/30541559 https://www.proquest.com/docview/2158154036 https://www.proquest.com/docview/2155942711 https://pubmed.ncbi.nlm.nih.gov/PMC6291946 https://doaj.org/article/1f4f9a5666364f87a8cd7a71a14a369b |
| Volume | 19 |
| WOSCitedRecordID | wos000453061900003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: RBZ dateStart: 20000101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: Open Access资源_DOAJ customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: DOA dateStart: 20000101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest - Publicly Available Content Database customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLink Journals customDbUrl: eissn: 1465-993X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017875 issn: 1465-993X databaseCode: RSV dateStart: 20000401 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdgIMQL4pvAqIyEhASKFseOPx73CUhbVw2YuifLduJRaSSo7fj7uUvSsgwBL7xUcu0otu_rd7rLHSGvvSpK7p1KhRd5KoKQqTM-Sz14I54FEWSbIHt6qMZjPZ2ayZVWX5gT1pUH7i5ui0URjQPQIbkUUSunQ6mcYo4Jx6XxqH0B9aycqT5-AGxY9DFMpuXWAq0aus0Y6pegeAZWqC3W_7tKvmKTrudLXguatrbo4D6514NIut1t_gG5UdUPyZ2jPkz-iJwB8WmXqUGbSLuPexd02dD3x4d7FIxhhT3rKCDD84o2Nb1o6nOKSpp-a-Z-VuKkq0scLVugTmc13T2e7D0mXw72P-9-SPseCmmQGV-mJvOV0SqGYKIBLzrnhsUolYItBM9dZrjPchdKWQXNIy_BnmdBF8GxEkOo_AnZqJu6ekao5zGLIpTRMCdixbwE5aQZIDrpOZA1IdnqTm3oC4xjn4sL2zoaWtqODBbIYJEMlifk7fqR7111jb8t3kFCrRdiYez2D2AX27OL_Re7JOQNktmi-MLmguu_QoAjYiEsu11I07qZKiGbg5UgdmE4vWIU24v9wgJ-0oBJARUk5NV6Gp_EVLa6ai7bNYURuWIsIU87vlofCZQvAjyTEDXguMGZhzP17GtbFFzmhhkB73234s1f2_rjlT7_H1f6gtzNUbIYdsnZJBvL-WX1ktwOP5azxXxEbqqpan_1iNza2R9PTkatrMJo8vFocgajk0-nPwEIjz6P |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQcCF9yNQwEggJFDUOHHs-IBQ6VJadfs4FLScjO3Ey0olKbtbEH-K38hMHltSRG89cNy1s5vJfvN9M-uxh5BnVqZ5Yo0MueVxyB0XoVE2Ci1kI5Y57kRdIPtxKHd3s9FI7S-RX91eGCyr7DixJuq8cvgf-SpIUwZyD4T75uhbiF2jcHW1a6HRwGK7-PkDUrbZ660B_L7P43jj3cH6Zth2FQidiJJ5qCJbQKLtnVNeQV4ZJ4p5L6T0YI1NDKT4NoqNy0XhssQnOShc5LLUGZbjomICn3uBXAQel1hCJkeLBI8B-NNmN1MaKhWzdhWVZWJ1hrqKiTsWGwigvp4O1u0C_haFP1TxdMXmqWXbWg03rv9vz_EGudbG3XStcZSbZKkob5HLO21lwW3yCfyFNsUttPK02Q89o_OKvt8bDijEDwW2-aMQTI8LWpX0sCrHFHWNfq2mdpLjoClzfDWvcxs6Ken63v7gDvlwLobdJctlVRb3CbWJjzx3uVfMcF8wK4DPMwZBsLAJeEJAog4E2rVnsmNrkENd52aZ0A1uNOBGI250EpCXi0uOmgNJzpr8FpG1mIhniddvVNOxbqlJM8-9MhDWi0Rwn0mTuVwayQzjJhHKBuQF4lIj48HNOdNu3AAT8ewwvZYKVWfmMiArvZnAVK4_3EFSt0w50yd4DMjTxTBeidV_ZVEd13NSxWPJWEDuNY6wMAn0CmNiFRDZc5Gezf2RcvKlPkddxIopDt_7qnOmk9v65yN9cLYRT8iVzYOdoR5u7W4_JFdjdHiG7YNWyPJ8elw8Ipfc9_lkNn1cUwcln8_bx34DFDinTw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdgoIkXvmGBAUZCQgJFi2PXjh_HSgFRukrANJ4s24m7SiOZmoy_n7skLWR8SIjHxGfFdn4-_053viPkmVOjnDurYuFEGgsvZGy1S2IH1ohjXnjZBsgeTdVslh0f63lf57ReR7uvXZLdnQbM0lQ2e2d56LZ4JvdqPKXQDEbXvQRFcplcEVgzCM31j0cbNwKgcdS7Mn_bbXAYtTn7f9XMPx1NF8MmL_hO2yNpcuO_J3OTXO_ZKN3v4HOLXCrK22T7Q-9vv0O-AIpoF_JBq0C7W8I1bSr65nA6pnCqFlj8jgLFXBS0KulpVS4oanv6tVq5ZY6NtszxqWkZP12W9OBwPr5LPk9efzp4G_fFGGIvE97EOnGFzlTwXgcN5njKNQtBKgVD8I7bRHOXpNbnsvAZDzwHYpD4bOQty9EXy--RrbIqix1CHQ9JED4PmlkRCuYkaLmMATWUjgM-IpKs_4rxfaZyLJhxalqLJZOmWzIDS2ZwyQyPyItNl7MuTcffhF_hr94IYobt9kW1Wph-wxoWRNAWyK7kUoRM2cznyipmmbBcaheR5wgUg3oABudtf50BpogZtcz-SOrWXlUR2R1Iwv71w-Y11EyvP2oDRCwDcgv0IiJPN83YE2PiyqI6b2VGWqSKsYjc75C5mRJocWSKOiJqgNnBnIct5fKkzS4uU820gO--XCP3x7D-uKQP_kn6Cdmejydm-m72_iG5liLyGZbY2SVbzeq8eESu-m_Nsl49bnfzd_xSR-Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effect+of+changes+to+GOLD+severity+stage+on+long+term+morbidity+and+mortality+in+COPD&rft.jtitle=Respiratory+research&rft.au=Flynn%2C+Robert+W.+V.&rft.au=MacDonald%2C+Thomas+M.&rft.au=Chalmers%2C+James+D.&rft.au=Schembri%2C+Stuart&rft.date=2018-12-12&rft.issn=1465-993X&rft.eissn=1465-993X&rft.volume=19&rft.issue=1&rft_id=info:doi/10.1186%2Fs12931-018-0960-3&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12931_018_0960_3 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-993X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-993X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-993X&client=summon |